Clinical Summary: Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study
Patients with subthreshold or mild-to-moderate depressive symptoms are common in primary care, yet standard antidepressants offer limited benefit when baseline severity is low. This study tests a once-daily combination of SAMe and Lactobacillus plantarum HEAL9 in that clinically relevant gap, with early symptom change and short-term tolerability as the main practical questions.
Key Findings
- Compared to placebo, SAMe plus L. plantarum HEAL9 produced a greater reduction in Z-SDS total score at treatment week 6 (P = .0165), meeting the primary endpoint.
- At treatment week 6, the core depressive factor on the Z-SDS also improved more with the combination than with placebo (P = .0247).
- An early treatment effect was seen by week 2, with greater reduction in Z-SDS total score for SAMe plus L. plantarum HEAL9 versus placebo (P = .0330).
- At week 2, the combination outperformed placebo on Z-SDS cognitive and anxiety factors (P = .0133 and P = .0459, respectively) and on Z-SAS total score (P = .0345), but the Z-SAS difference was not significant at end of treatment (P = .3418).
- Within the active-treatment group, baseline depression severity did not correlate with change in Z-SDS total score at the end of treatment (ρ = 0.01, P = .9684); compliance ≥ 80% was recorded for 95.6% of treated patients, and adverse events occurred in 2 subjects treated with the new combination and 1 subject treated with placebo, with no treatment-related adverse events.
For adults with subthreshold or mild-to-moderate depressive symptoms, once-daily SAMe 200 mg plus L. plantarum HEAL9 1 ×— 109 CFU improved self-rated depressive symptoms versus placebo within 2 weeks and at 6 weeks, with no treatment-related adverse events reported in this short trial. The clearest benefits were on overall depressive symptoms and core depressive features rather than across every associated symptom domain.
Practice Implications
- Consider this combination for patients with mild-to-moderate depressive symptoms who are not ideal candidates for standard antidepressants, especially when a rapid change by day 14 would influence management.
- Set expectations that benefits were strongest on Z-SDS depressive outcomes; insomnia, EQ-5D-3L, and end-of-treatment anxiety outcomes did not show a significant between-group advantage.
- Use the studied regimen and timeframe when discussing treatment: 1 tablet daily for 42 consecutive days containing SAMe 200 mg and L. plantarum HEAL9 1 ×— 109 CFU.
- Monitor symptoms with structured self-report scales when possible, since the trial relied on patient-reported outcomes and enrolled patients with Z-SDS raw scores between 41 and 55.
